GB2469791B - Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease - Google Patents

Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease

Info

Publication number
GB2469791B
GB2469791B GB0906971.7A GB0906971A GB2469791B GB 2469791 B GB2469791 B GB 2469791B GB 0906971 A GB0906971 A GB 0906971A GB 2469791 B GB2469791 B GB 2469791B
Authority
GB
United Kingdom
Prior art keywords
treatment
neoplastic disease
compounds providing
transmucosal formulation
providing dihydroartemesinin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0906971.7A
Other versions
GB0906971D0 (en
GB2469791A (en
Inventor
Calvin John Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LondonPharma Ltd
Original Assignee
LondonPharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LondonPharma Ltd filed Critical LondonPharma Ltd
Priority to GB0906971.7A priority Critical patent/GB2469791B/en
Publication of GB0906971D0 publication Critical patent/GB0906971D0/en
Priority to PCT/GB2010/050672 priority patent/WO2010122356A1/en
Priority to CN201080017965.1A priority patent/CN102395362B/en
Priority to MX2011010961A priority patent/MX2011010961A/en
Priority to MYPI2011005080A priority patent/MY155646A/en
Priority to NZ595469A priority patent/NZ595469A/en
Priority to AU2010240654A priority patent/AU2010240654C1/en
Priority to RS20120393A priority patent/RS52430B/en
Priority to DK10715337.1T priority patent/DK2424523T3/en
Priority to BRPI1014887A priority patent/BRPI1014887A8/en
Priority to ES10715337T priority patent/ES2390046T3/en
Priority to US13/265,518 priority patent/US20120157518A1/en
Priority to JP2012506584A priority patent/JP5795760B2/en
Priority to SI201030076T priority patent/SI2424523T1/en
Priority to CA2756925A priority patent/CA2756925A1/en
Priority to PT10715337T priority patent/PT2424523E/en
Priority to MEP-2012-393A priority patent/ME02008B/en
Priority to PL10715337T priority patent/PL2424523T3/en
Priority to EP10715337A priority patent/EP2424523B1/en
Priority to RU2011139637/15A priority patent/RU2501550C2/en
Priority to SG2011073954A priority patent/SG175162A1/en
Publication of GB2469791A publication Critical patent/GB2469791A/en
Priority to ZA2011/07088A priority patent/ZA201107088B/en
Priority to IL215453A priority patent/IL215453A/en
Publication of GB2469791B publication Critical patent/GB2469791B/en
Application granted granted Critical
Priority to HK12104912.3A priority patent/HK1164140A1/en
Priority to HRP20120711AT priority patent/HRP20120711T1/en
Priority to US14/813,424 priority patent/US20160022629A1/en
Priority to US15/697,240 priority patent/US20170368023A1/en
Priority to US16/164,610 priority patent/US20190142737A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
GB0906971.7A 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease Expired - Fee Related GB2469791B (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
GB0906971.7A GB2469791B (en) 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease
CA2756925A CA2756925A1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
MEP-2012-393A ME02008B (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
MX2011010961A MX2011010961A (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin.
MYPI2011005080A MY155646A (en) 2009-04-23 2010-04-23 Pharmaceutical preparation
NZ595469A NZ595469A (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
AU2010240654A AU2010240654C1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
PL10715337T PL2424523T3 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
DK10715337.1T DK2424523T3 (en) 2009-04-23 2010-04-23 Sublingual spray formulation with dihydroartemisinin
BRPI1014887A BRPI1014887A8 (en) 2009-04-23 2010-04-23 pharmaceutical composition for use in treating neoplasms and use of a compound providing dihydroartemesinin via sublingual, transmucosal, buccal or nasal dosage
ES10715337T ES2390046T3 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
US13/265,518 US20120157518A1 (en) 2009-04-23 2010-04-23 Sublingual Spray Formulation Comprising Dihydroartemesinin
CN201080017965.1A CN102395362B (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
SI201030076T SI2424523T1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
PCT/GB2010/050672 WO2010122356A1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
PT10715337T PT2424523E (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
JP2012506584A JP5795760B2 (en) 2009-04-23 2010-04-23 Sublingual spray formulation containing dihydroartemisinin
RS20120393A RS52430B (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
EP10715337A EP2424523B1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
RU2011139637/15A RU2501550C2 (en) 2009-04-23 2010-04-23 Sublingual spray composition containing dihydroartemisinin
SG2011073954A SG175162A1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
ZA2011/07088A ZA201107088B (en) 2009-04-23 2011-09-28 Sublingual spray formulation comprising dihydroartemesinin
IL215453A IL215453A (en) 2009-04-23 2011-10-02 Sublingual spray formulation comprising dihydroartemesinin
HK12104912.3A HK1164140A1 (en) 2009-04-23 2012-05-18 Sublingual spray formulation comprising dihydroartemesinin
HRP20120711AT HRP20120711T1 (en) 2009-04-23 2012-09-06 Sublingual spray formulation comprising dihydroartemesinin
US14/813,424 US20160022629A1 (en) 2009-04-23 2015-07-30 Sublingual Spray Formulation Comprising Dihydroartemesinin
US15/697,240 US20170368023A1 (en) 2009-04-23 2017-09-06 Sublingual spray formulation comprising dihydroartemesinin
US16/164,610 US20190142737A1 (en) 2009-04-23 2018-10-18 Sublingual spray formulation comprising dihydroartemesinin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0906971.7A GB2469791B (en) 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease

Publications (3)

Publication Number Publication Date
GB0906971D0 GB0906971D0 (en) 2009-06-03
GB2469791A GB2469791A (en) 2010-11-03
GB2469791B true GB2469791B (en) 2011-12-14

Family

ID=40774834

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0906971.7A Expired - Fee Related GB2469791B (en) 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease

Country Status (1)

Country Link
GB (1) GB2469791B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
US6306896B1 (en) * 1997-11-03 2001-10-23 Mepha Ag Pharmaceutically active composition containing artemisinine and/or derivative of artemisinine
US6307068B1 (en) * 1998-06-17 2001-10-23 Adir Et Compagnie Artemisinin derivatives, method for the preparation thereof and pharmaceutical compositions containing the same
WO2003103588A2 (en) * 2002-06-06 2003-12-18 University Of Washington Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
WO2007043057A2 (en) * 2005-10-11 2007-04-19 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
GB2454567A (en) * 2007-10-25 2009-05-13 Protopharma Ltd Anti-Malarial Composition containing artemether or arteether

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
US6306896B1 (en) * 1997-11-03 2001-10-23 Mepha Ag Pharmaceutically active composition containing artemisinine and/or derivative of artemisinine
US6307068B1 (en) * 1998-06-17 2001-10-23 Adir Et Compagnie Artemisinin derivatives, method for the preparation thereof and pharmaceutical compositions containing the same
WO2003103588A2 (en) * 2002-06-06 2003-12-18 University Of Washington Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
WO2007043057A2 (en) * 2005-10-11 2007-04-19 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
GB2454567A (en) * 2007-10-25 2009-05-13 Protopharma Ltd Anti-Malarial Composition containing artemether or arteether

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Research, Vol. 65, No. 23, 2005, (Disbrow Gary L; Baege Astrid C; Kierpiec Katie A; Yuan Hang; Centeno Jose A; Thibodeaux Clare A; Hartmann Dan; Schlegel Richard), pages 10854-10861, ISSN 0008-5472 *
International Journal Of Parasitology, Vol. 24, No. 4, 1994, (Janse C J; Waters A P; Kos J; Lugt C B), pages 589-594, ISSN 0020-7519 *
International Journal Of Parasitology, Vol. 36, 2006, (Touitou E; Waknine J H; Godin B; Golenser J), pages 1493-1498, ISSN 0020-7519 *

Also Published As

Publication number Publication date
GB0906971D0 (en) 2009-06-03
GB2469791A (en) 2010-11-03

Similar Documents

Publication Publication Date Title
IL249941A0 (en) Spiro-oxindole compounds and their use as therapeutic agents
HK1153926A1 (en) Purin derivatives for use in the treatment of fab-related diseases fab-
IL264349B1 (en) Regimen comprising neratinib for the treatment of cancer
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
IL196745A (en) Idebenone for use in transmucosal administration for use in the treatment of diseases
IL207965A (en) Compounds for use in the treatment or prophylaxis of pain
HK1151971A1 (en) Compounds for use in the treatment of cancer
GB0822486D0 (en) Compounds for use in the treatment of pain
HRP20151393T8 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
IL200753A (en) Pharmaceutical composition comprising ib-meca for the treatment of psoriasis
GB0901465D0 (en) Compounds for use in therapy
HK1214771A1 (en) Formulations for use in the treatment of skin conditions
EP2363132A4 (en) The use of sophoricoside in preparing medicaments
GB2469791B (en) Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease
GB201016486D0 (en) Compounds for the use in treatment of plants
GB0802128D0 (en) Therapeutic compounds and their use
PL2229943T3 (en) Compounds for use in the treatment of peripheral neuropathy
GB2482615B (en) Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of Lyme disease
GB2466110B (en) Antibacterial formulation for use in the treatment of acne
GB2482431B (en) Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of fluke infestation
GB2473735B (en) Skin treatment formulation
GB0819037D0 (en) Skin treatment formulation
GB0913300D0 (en) Therapeutic compounds and their use
GB0821274D0 (en) Compounds for use in therapy

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: LONDONPHARMA LIMITED

Free format text: FORMER OWNER: CALVIN JOHN ROSS

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20210423

S28 Restoration of ceased patents (sect. 28/pat. act 1977)

Free format text: APPLICATION FILED

S28 Restoration of ceased patents (sect. 28/pat. act 1977)

Free format text: RESTORATION ALLOWED

Effective date: 20220511

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20230423